Şizofrenide Uzun Etkili Enjektabl Antipsikotikler: Klinik Kullanım ve Kanıtlar
Özet
Referanslar
Soygür H, Alptekin K, Atbaşoğlu EC, et al. Şizofreni ve diğer psikotik bozukluklar. 1. Baskı. Ankara: Türkiye Psikiyatri Derneği Yayınları; 2007.
Ngubane NP, Mabandla MV, De Gama BZ. The antipsychotic potential of Salix mucronata on ketamine-induced rats. IBRO Neuroscience Reports. 2024;17:96–107. doi:10.1016/j.ibneur.2024.01.012
Uzbay T. Şizofreni tedavisinde yeni bir hedef: agmatin ve beyin poliamin sistemi. Klinik Psikiyatri. 2009;12:188–196.
Binbay T, Ulaş H, Elbi H, et al. The psychosis epidemiology in Turkey: a systematic review on prevalence estimates and admission rates. Turkish Journal of Psychiatry. 2011;22(1):40–52.
Nasrallah HA, Smeltzer DJ. Contemporary diagnosis and management of the patient with schizophrenia. Pennsylvania: Handbooks in Health Care Company; 2003.
Penttilä M, Jääskeläinen E, Hirvonen N, et al. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry. 2014;205(2):88–94. doi:10.1192/bjp.bp.113.127753
Mullins CD, Obeidat NA, Cuffel BJ, et al. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophrenia Research. 2008;98(1–3):8–15. doi:10.1016/j.schres.2007.08.007
Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. 4th ed. Cambridge: Cambridge University Press; 2013.
Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: An overview. CNS Drugs. 2021;35(1):39. doi:10.1007/s40263-020-00779-5.
Park EJ, Amatya S, Kim MS, et al. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Archives of Pharmacal Research. 2013;36(6):651–659. doi:10.1007/s12272-013-0090-5
Kenakin TP. A pharmacology primer: theory, application, and methods. 4th ed. Amsterdam: Academic Press; 2014.
Spanarello S, Ferla T. The pharmacokinetics of long-acting antipsychotic medications. Current Clinical Pharmacology. 2014;9(3):310–317. doi:10.2174/15748847113089990054
Sheehan JJ, Reilly KR, Fu DJ, et al. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innovations in Clinical Neuroscience. 2012;9(7–8):17–23.
Taylor D, Barnes TRE, Young AH. Maudsley psikiyatride reçeteleme rehberi. 14. Baskı. Ankara: EMA Tıp Kitabevi; 2021.
Johnson DAW. Historical perspective on antipsychotic long-acting injections. British Journal of Psychiatry Supplement. 2009;52:7–12. doi:10.1192/bjp.195.52.s7
Denham J, Adamson L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatrica Scandinavica. 1971;47(4):420–430. doi:10.1111/j.1600-0447.1971.tb02010.x
Gottfries CG, Green L. Flupenthixol decanoate in the treatment of out-patients. Acta Psychiatrica Scandinavica Supplementum. 1974;255:15–24.
Crocq MA. A history of antipsychotic long-acting injections in the treatment of schizophrenia. L’Encéphale. 2015;41(1):84–92. doi:10.1016/j.encep.2014.04.003
Marder SR. Facilitating compliance with antipsychotic medication. Journal of Clinical Psychiatry. 1998;59(Suppl 3):21–25.
Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? American Journal of Psychiatry. 2002;159(1):103–108. doi:10.1176/appi.ajp.159.1.103
Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry. 2003;160(6):1125–1132. doi:10.1176/appi.ajp.160.6.1125
Herold R, Szekeres G, Bitter I. Continuous maintenance antipsychotic treatment in schizophrenia. Psychiatria Hungarica. 2017;32(3):296–306.
Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. American Journal of Psychiatry. 2018;175(8):765–773. doi:10.1176/appi.ajp.2018.17091001
Correll CU, Rubio JM, Kane JM. What is the risk–benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149–160. doi:10.1002/wps.20516
Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry. 2020;177(9):868–872. doi:10.1176/appi.ajp.2020.177901
Alvarez-Jimenez M, Priede A, Hetrick SE, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophrenia Research. 2012;139(1–3):116–128. doi:10.1016/j.schres.2012.05.007
Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services. 2004;55(8):886–891. doi:10.1176/appi.ps.55.8.886
Kim B, Lee SH, Choi TK, et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in a naturalistic setting. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008;32(5):1231–1235. doi:10.1016/j.pnpbp.2008.03.010
Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry. 2011;168(6):603–609. doi:10.1176/appi.ajp.2011.10081224
Meltzer HY, Baldessarini RJ. Antipsychotic and anticholinergic drugs. In: Gelder MG, Andreasen NC, Lopez-Ibor JJ, Geddes JR (eds.). New Oxford textbook of psychiatry. Oxford: Oxford University Press; 2009. p. 1208–1231.
Fleischhacker WW, Miyamoto S. Pharmacological treatment of schizophrenia. Clinical Neuropsychopharmacology and Therapeutics. 2016;7:1–8.
Wang D, Schneider-Thoma J, Siafis S, et al. Long-acting injectable second-generation antipsychotics versus placebo and their oral formulations in acute schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. Schizophrenia Bulletin. 2024;50(1):132–145. doi:10.1093/schbul/sbad137
Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder. BMJ. 2006;333(7561):224–227. doi:10.1136/bmj.38881.382755.2F
Crump C, Winkleby MA, Sundquist K, et al. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. American Journal of Psychiatry. 2013;170(3):324–333. doi:10.1176/appi.ajp.2012.12050599
Vanasse A, Blais L, Courteau J, et al. Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatrica Scandinavica. 2016;134(5):374–384. doi:10.1111/acps.12606
Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of patients with schizophrenia. Schizophrenia Research. 2018;197:274–280. doi:10.1016/j.schres.2017.12.010
Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophrenia Bulletin. 2015;41(3):656–663. doi:10.1093/schbul/sbu164
Pietrini F, Spadafora M, Tatini L, et al. LAI versus oral: a case-control study on subjective experience of antipsychotic maintenance treatment. European Psychiatry. 2016;37:35–42. doi:10.1016/j.eurpsy.2016.04.006
Lloyd K, Latif MA, Simpson S, et al. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Human Psychopharmacology. 2010;25(3):243–252. doi:10.1002/hup.1113
Hargarter L, Cherubin P, Bergmans P, et al. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2015;58:1–7. doi:10.1016/j.pnpbp.2014.11.012
Correll CU, Johnston K, Turkoz I, et al. Three-year outcomes of 6-month paliperidone palmitate in adults with schizophrenia: an open-label extension study. JAMA Network Open. 2024;7(7):e2421495. doi:10.1001/jamanetworkopen.2024.21495
Aascher-Ssvanum H, Novick D, Haro JM, et al. Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection. Neuropsychiatric Disease and Treatment. 2014;10:1125–1131. doi:10.2147/NDT.S63501
Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophrenia Research. 2015;168(1–2):498–504. doi:10.1016/j.schres.2015.07.020
İnanç L, Demir Özdemir A, Güleç H, et al. Şizofreni ve bipolar bozukluk hastalarında depo antipsikotik kullanımının etkinliği ve güvenirliği. Çukurova Medical Journal. 2018;43(Ek 1):38–43.
Lin J, Wong B, Offord S, et al. Healthcare cost reductions associated with the use of long-acting injectable formulations of antipsychotic medications versus oral among patients with schizophrenia. Journal of Behavioral Health Services and Research. 2013;40(3):355–366. doi:10.1007/s11414-013-9331-4
46.Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. Journal of Clinical Psychiatry. 2005;66(9):1122–1129.
Offord S, Wong B, Mirski D, et al. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics versus oral. Journal of Medical Economics. 2013;16(2):231–239. doi:10.3111/13696998.2012.751025
McCutcheon R, Beck K, D’Ambrosio E, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatrica Scandinavica. 2018;137(1):39–46. doi:10.1111/acps.12824
Haddad P, Lambert T, Lauriello J. Antipsychotic long-acting injections. London: Springer Healthcare; 2016.
Patel MX, De Zoysa N, Bernadt M, et al. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. Journal of Psychopharmacology. 2009;23(7):789–796. doi:10.1177/0269881108092124
Das AK, Malik A, Haddad PM. A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Therapeutic Advances in Psychopharmacology. 2014;4(5):179–185. doi:10.1177/2045125314540293
Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opinion on Pharmacotherapy. 2010;11(14):2301–2317. doi:10.1517/14656566.2010.505202
Brissos S, Veguilla MR, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology. 2014;4(5):198–219. doi:10.1177/2045125314540297
Özgüven HD, Kir Y. Uzun etkili enjeksiyon antipsikotiklerin şizofreni ve bipolar bozukluk tedavisindeki yeri. Noropsikiyatri Arşivi. 2021;58(Suppl 1):47–52. doi:10.29399/npa.27419
Guinart D, Taipale H, Rubio JM, et al. Risk factors, incidence, and outcomes of neuroleptic malignant syndrome on long-acting injectable versus oral antipsychotics. Schizophrenia Bulletin. 2021;47(6):1621–1630. doi:10.1093/schbul/sbab072
Gopal S, Gassmann-Mayer C, Palumbo J, et al. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Current Medical Research and Opinion. 2010;26(2):377–387. doi:10.1185/03007990903422338
Kane JM, McEvoy JP, Correll CU, et al. Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. CNS Drugs. 2021;35(11):1189–1205. doi:10.1007/s40263-021-00863-5
de Filippis R, De Fazio P, Gaetano R, et al. Current and emerging long-acting antipsychotics for the treatment of schizophrenia. Expert Opinion on Drug Safety. 2021;20(7):771–790. doi:10.1080/14740338.2021.1910674
Perkins DO, Gu H, Weiden PJ, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia. Journal of Clinical Psychiatry. 2008;69(1):106–113.
Bozzatello P, Bellino S, Rocca P. Predictive factors of treatment resistance in first episode of psychosis: a systematic review. Frontiers in Psychiatry. 2019;10:67. doi:10.3389/fpsyt.2019.00067
Hany M, Rehman B, Azhar Y, et al. Schizophrenia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
Stevens GL, Dawson G, Zummo J. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. Early Intervention in Psychiatry. 2016;10(5):365–377. doi:10.1111/eip.12278
Emsley R, Chiliza B, Asmal L, et al. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Intervention in Psychiatry. 2013;7(3):247–254. doi:10.1111/eip.12041
Kim B, Lee SH, Yang YK, et al. Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons. Schizophrenia Research and Treatment. 2012;2012:1–8. doi:10.1155/2012/560836
Lian L, Kim DD, Procyshyn RM, et al. Long-acting injectable antipsychotics for early psychosis: a comprehensive systematic review. PLoS One. 2022;17(4):e0267808. doi:10.1371/journal.pone.0267808
Bioque M, Parellada E, García-Rizo C, et al. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders. European Psychiatry. 2020;63(1):e50. doi:10.1192/j.eurpsy.2020.48
Youykheang M, Al Hallaq Z, Menelas K, et al. Combination of long-acting injectable antipsychotics in the treatment of psychiatric disorders. Journal of Clinical Psychopharmacology. 2023;43(1):20–27. doi:10.1097/JCP.0000000000001548
Lin TC, Lin CH. Schizophrenia patients discharged on clozapine plus long-acting injectable antipsychotics from a public psychiatric hospital in Taiwan, 2006–2021. International Journal of Neuropsychopharmacology. 2023;26(11):808–816. doi:10.1093/ijnp/pyad045
Lin CH, Chen FC, Chan HY, et al. A comparison of long-acting injectable antipsychotics with oral antipsychotics on time to rehospitalization within 1 year of discharge in elderly patients with schizophrenia. American Journal of Geriatric Psychiatry. 2020;28(1):23–30. doi:10.1016/j.jagp.2019.08.006
Correll CU, Benson C, Emond B, et al. Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophrenia. 2023;9(1):1–12. doi:10.1038/s41537-023-00360-5
Referanslar
Soygür H, Alptekin K, Atbaşoğlu EC, et al. Şizofreni ve diğer psikotik bozukluklar. 1. Baskı. Ankara: Türkiye Psikiyatri Derneği Yayınları; 2007.
Ngubane NP, Mabandla MV, De Gama BZ. The antipsychotic potential of Salix mucronata on ketamine-induced rats. IBRO Neuroscience Reports. 2024;17:96–107. doi:10.1016/j.ibneur.2024.01.012
Uzbay T. Şizofreni tedavisinde yeni bir hedef: agmatin ve beyin poliamin sistemi. Klinik Psikiyatri. 2009;12:188–196.
Binbay T, Ulaş H, Elbi H, et al. The psychosis epidemiology in Turkey: a systematic review on prevalence estimates and admission rates. Turkish Journal of Psychiatry. 2011;22(1):40–52.
Nasrallah HA, Smeltzer DJ. Contemporary diagnosis and management of the patient with schizophrenia. Pennsylvania: Handbooks in Health Care Company; 2003.
Penttilä M, Jääskeläinen E, Hirvonen N, et al. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry. 2014;205(2):88–94. doi:10.1192/bjp.bp.113.127753
Mullins CD, Obeidat NA, Cuffel BJ, et al. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophrenia Research. 2008;98(1–3):8–15. doi:10.1016/j.schres.2007.08.007
Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. 4th ed. Cambridge: Cambridge University Press; 2013.
Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: An overview. CNS Drugs. 2021;35(1):39. doi:10.1007/s40263-020-00779-5.
Park EJ, Amatya S, Kim MS, et al. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Archives of Pharmacal Research. 2013;36(6):651–659. doi:10.1007/s12272-013-0090-5
Kenakin TP. A pharmacology primer: theory, application, and methods. 4th ed. Amsterdam: Academic Press; 2014.
Spanarello S, Ferla T. The pharmacokinetics of long-acting antipsychotic medications. Current Clinical Pharmacology. 2014;9(3):310–317. doi:10.2174/15748847113089990054
Sheehan JJ, Reilly KR, Fu DJ, et al. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innovations in Clinical Neuroscience. 2012;9(7–8):17–23.
Taylor D, Barnes TRE, Young AH. Maudsley psikiyatride reçeteleme rehberi. 14. Baskı. Ankara: EMA Tıp Kitabevi; 2021.
Johnson DAW. Historical perspective on antipsychotic long-acting injections. British Journal of Psychiatry Supplement. 2009;52:7–12. doi:10.1192/bjp.195.52.s7
Denham J, Adamson L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatrica Scandinavica. 1971;47(4):420–430. doi:10.1111/j.1600-0447.1971.tb02010.x
Gottfries CG, Green L. Flupenthixol decanoate in the treatment of out-patients. Acta Psychiatrica Scandinavica Supplementum. 1974;255:15–24.
Crocq MA. A history of antipsychotic long-acting injections in the treatment of schizophrenia. L’Encéphale. 2015;41(1):84–92. doi:10.1016/j.encep.2014.04.003
Marder SR. Facilitating compliance with antipsychotic medication. Journal of Clinical Psychiatry. 1998;59(Suppl 3):21–25.
Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? American Journal of Psychiatry. 2002;159(1):103–108. doi:10.1176/appi.ajp.159.1.103
Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry. 2003;160(6):1125–1132. doi:10.1176/appi.ajp.160.6.1125
Herold R, Szekeres G, Bitter I. Continuous maintenance antipsychotic treatment in schizophrenia. Psychiatria Hungarica. 2017;32(3):296–306.
Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. American Journal of Psychiatry. 2018;175(8):765–773. doi:10.1176/appi.ajp.2018.17091001
Correll CU, Rubio JM, Kane JM. What is the risk–benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149–160. doi:10.1002/wps.20516
Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry. 2020;177(9):868–872. doi:10.1176/appi.ajp.2020.177901
Alvarez-Jimenez M, Priede A, Hetrick SE, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophrenia Research. 2012;139(1–3):116–128. doi:10.1016/j.schres.2012.05.007
Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services. 2004;55(8):886–891. doi:10.1176/appi.ps.55.8.886
Kim B, Lee SH, Choi TK, et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in a naturalistic setting. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008;32(5):1231–1235. doi:10.1016/j.pnpbp.2008.03.010
Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry. 2011;168(6):603–609. doi:10.1176/appi.ajp.2011.10081224
Meltzer HY, Baldessarini RJ. Antipsychotic and anticholinergic drugs. In: Gelder MG, Andreasen NC, Lopez-Ibor JJ, Geddes JR (eds.). New Oxford textbook of psychiatry. Oxford: Oxford University Press; 2009. p. 1208–1231.
Fleischhacker WW, Miyamoto S. Pharmacological treatment of schizophrenia. Clinical Neuropsychopharmacology and Therapeutics. 2016;7:1–8.
Wang D, Schneider-Thoma J, Siafis S, et al. Long-acting injectable second-generation antipsychotics versus placebo and their oral formulations in acute schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. Schizophrenia Bulletin. 2024;50(1):132–145. doi:10.1093/schbul/sbad137
Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder. BMJ. 2006;333(7561):224–227. doi:10.1136/bmj.38881.382755.2F
Crump C, Winkleby MA, Sundquist K, et al. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. American Journal of Psychiatry. 2013;170(3):324–333. doi:10.1176/appi.ajp.2012.12050599
Vanasse A, Blais L, Courteau J, et al. Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatrica Scandinavica. 2016;134(5):374–384. doi:10.1111/acps.12606
Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of patients with schizophrenia. Schizophrenia Research. 2018;197:274–280. doi:10.1016/j.schres.2017.12.010
Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophrenia Bulletin. 2015;41(3):656–663. doi:10.1093/schbul/sbu164
Pietrini F, Spadafora M, Tatini L, et al. LAI versus oral: a case-control study on subjective experience of antipsychotic maintenance treatment. European Psychiatry. 2016;37:35–42. doi:10.1016/j.eurpsy.2016.04.006
Lloyd K, Latif MA, Simpson S, et al. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Human Psychopharmacology. 2010;25(3):243–252. doi:10.1002/hup.1113
Hargarter L, Cherubin P, Bergmans P, et al. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2015;58:1–7. doi:10.1016/j.pnpbp.2014.11.012
Correll CU, Johnston K, Turkoz I, et al. Three-year outcomes of 6-month paliperidone palmitate in adults with schizophrenia: an open-label extension study. JAMA Network Open. 2024;7(7):e2421495. doi:10.1001/jamanetworkopen.2024.21495
Aascher-Ssvanum H, Novick D, Haro JM, et al. Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection. Neuropsychiatric Disease and Treatment. 2014;10:1125–1131. doi:10.2147/NDT.S63501
Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophrenia Research. 2015;168(1–2):498–504. doi:10.1016/j.schres.2015.07.020
İnanç L, Demir Özdemir A, Güleç H, et al. Şizofreni ve bipolar bozukluk hastalarında depo antipsikotik kullanımının etkinliği ve güvenirliği. Çukurova Medical Journal. 2018;43(Ek 1):38–43.
Lin J, Wong B, Offord S, et al. Healthcare cost reductions associated with the use of long-acting injectable formulations of antipsychotic medications versus oral among patients with schizophrenia. Journal of Behavioral Health Services and Research. 2013;40(3):355–366. doi:10.1007/s11414-013-9331-4
46.Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. Journal of Clinical Psychiatry. 2005;66(9):1122–1129.
Offord S, Wong B, Mirski D, et al. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics versus oral. Journal of Medical Economics. 2013;16(2):231–239. doi:10.3111/13696998.2012.751025
McCutcheon R, Beck K, D’Ambrosio E, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatrica Scandinavica. 2018;137(1):39–46. doi:10.1111/acps.12824
Haddad P, Lambert T, Lauriello J. Antipsychotic long-acting injections. London: Springer Healthcare; 2016.
Patel MX, De Zoysa N, Bernadt M, et al. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. Journal of Psychopharmacology. 2009;23(7):789–796. doi:10.1177/0269881108092124
Das AK, Malik A, Haddad PM. A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Therapeutic Advances in Psychopharmacology. 2014;4(5):179–185. doi:10.1177/2045125314540293
Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opinion on Pharmacotherapy. 2010;11(14):2301–2317. doi:10.1517/14656566.2010.505202
Brissos S, Veguilla MR, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology. 2014;4(5):198–219. doi:10.1177/2045125314540297
Özgüven HD, Kir Y. Uzun etkili enjeksiyon antipsikotiklerin şizofreni ve bipolar bozukluk tedavisindeki yeri. Noropsikiyatri Arşivi. 2021;58(Suppl 1):47–52. doi:10.29399/npa.27419
Guinart D, Taipale H, Rubio JM, et al. Risk factors, incidence, and outcomes of neuroleptic malignant syndrome on long-acting injectable versus oral antipsychotics. Schizophrenia Bulletin. 2021;47(6):1621–1630. doi:10.1093/schbul/sbab072
Gopal S, Gassmann-Mayer C, Palumbo J, et al. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Current Medical Research and Opinion. 2010;26(2):377–387. doi:10.1185/03007990903422338
Kane JM, McEvoy JP, Correll CU, et al. Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. CNS Drugs. 2021;35(11):1189–1205. doi:10.1007/s40263-021-00863-5
de Filippis R, De Fazio P, Gaetano R, et al. Current and emerging long-acting antipsychotics for the treatment of schizophrenia. Expert Opinion on Drug Safety. 2021;20(7):771–790. doi:10.1080/14740338.2021.1910674
Perkins DO, Gu H, Weiden PJ, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia. Journal of Clinical Psychiatry. 2008;69(1):106–113.
Bozzatello P, Bellino S, Rocca P. Predictive factors of treatment resistance in first episode of psychosis: a systematic review. Frontiers in Psychiatry. 2019;10:67. doi:10.3389/fpsyt.2019.00067
Hany M, Rehman B, Azhar Y, et al. Schizophrenia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
Stevens GL, Dawson G, Zummo J. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. Early Intervention in Psychiatry. 2016;10(5):365–377. doi:10.1111/eip.12278
Emsley R, Chiliza B, Asmal L, et al. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Intervention in Psychiatry. 2013;7(3):247–254. doi:10.1111/eip.12041
Kim B, Lee SH, Yang YK, et al. Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons. Schizophrenia Research and Treatment. 2012;2012:1–8. doi:10.1155/2012/560836
Lian L, Kim DD, Procyshyn RM, et al. Long-acting injectable antipsychotics for early psychosis: a comprehensive systematic review. PLoS One. 2022;17(4):e0267808. doi:10.1371/journal.pone.0267808
Bioque M, Parellada E, García-Rizo C, et al. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders. European Psychiatry. 2020;63(1):e50. doi:10.1192/j.eurpsy.2020.48
Youykheang M, Al Hallaq Z, Menelas K, et al. Combination of long-acting injectable antipsychotics in the treatment of psychiatric disorders. Journal of Clinical Psychopharmacology. 2023;43(1):20–27. doi:10.1097/JCP.0000000000001548
Lin TC, Lin CH. Schizophrenia patients discharged on clozapine plus long-acting injectable antipsychotics from a public psychiatric hospital in Taiwan, 2006–2021. International Journal of Neuropsychopharmacology. 2023;26(11):808–816. doi:10.1093/ijnp/pyad045
Lin CH, Chen FC, Chan HY, et al. A comparison of long-acting injectable antipsychotics with oral antipsychotics on time to rehospitalization within 1 year of discharge in elderly patients with schizophrenia. American Journal of Geriatric Psychiatry. 2020;28(1):23–30. doi:10.1016/j.jagp.2019.08.006
Correll CU, Benson C, Emond B, et al. Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophrenia. 2023;9(1):1–12. doi:10.1038/s41537-023-00360-5
